MedTrace Logo

Bacillus Subtilis in Parkinson's Disease

NCT06487975 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-04-08

No results posted yet for this study

Summary

The aim of this study is to evaluate whether the administration of Bacillus Subtilis influences gut and blood biomarkers relevant to the proposed mechanism(s) of action, as well as being acceptable as a regular supplement for people with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

DIETARY_SUPPLEMENT

Bacillus Subtilis

Bacillus Subtilis 1 capsule once daily in the morning (consisting of 10x10\^9 Colony Forming Units)

OTHER

Placebo

1 visually identical placebo capsule once daily in the morning using the same carrier (microcrystalline cellulose) as the active (but not containing Bacillus Subtilis)

Sponsors & Collaborators

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • ADM Protexin

    collaborator INDUSTRY

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David P Breen, MBChB · NHS Lothian

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2025-03-05
Completion
2025-11-20

Countries

  • Norway
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06487975 on ClinicalTrials.gov